14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
THOR vs HAE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
HAE Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)
HAE Overall Winner
6-Pillar Tally: THOR 0 – 5 HAE (1 Tie)
Matrix Metrics: THOR 1 – 9 HAE
As of Nov 20, 2026, Haemonetics Corporation (HAE) is the stronger overall head-to-head candidate over THOR (THOR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). THOR carries a Unified Composite Score of 44.5/100 (HOLD) at $24.63 (N/M Forward P/E, N/A operating margin), whereas HAE carries 49.2/100 (HOLD) at $120.16 (22.7x Forward P/E, 18.8% operating margin).
Technical & Structure Timing Caution: THOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.7); meanwhile HAE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on THOR vs HAE. Trailing 12-month operating profitability (THOR N/A vs HAE 18.8%) and valuation multiples (THOR N/M vs HAE 22.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
HAE Moat ProfileScale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $5.5B market capitalization and 18.8% operating margin.
OpEx & R&D Reinvestment41.0% of Rev ($567M)
90D Engineering Disclosures0 Published
Investor FAQ THOR vs HAE Key Questions & Quantitative Answers
As of Nov 20, 2026, Haemonetics Corporation (HAE) is the stronger overall head-to-head candidate over THOR (THOR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). THOR carries a Unified Composite Score of 44.5/100 (HOLD) at $24.63 (N/M Forward P/E, N/A operating margin), whereas HAE carries 49.2/100 (HOLD) at $120.16 (22.7x Forward P/E, 18.8% operating margin). Technical & Structure Timing Caution: THOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.7); meanwhile HAE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
HAE leads the Growth & Scale pillar: THOR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with HAE at +9.3% YoY revenue growth and +23.5% YoY earnings growth on $1.38B TTM revenue (59.8% gross margin, 18.8% operating margin). On trailing 12-month operating scale, THOR generates N/A in USD-normalized revenue versus $1.38B for HAE. In operating R&D and SG&A reinvestment, THOR deploys N/A (0 90-day corporate R&D disclosures) versus 41.0% of Rev ($567M) (0 disclosures) for HAE.
HAE screens cheaper on headline valuation multiples. THOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HAE trades at 22.7x Forward P/E, 53.3x Trailing P/E, 1.92x PEG, and 4.0x EV/Revenue (26.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against THOR (N/A ROE) versus HAE (11.9% ROE) capital efficiency.
In options market volatility and institutional positioning, THOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 17% Vol realized risk). By comparison, HAE carries 32.7% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 33% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.